Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 97.22% | -25.41% | -58.11% | -24.52% | -69.30% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | -- | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.98% | -35.76% | -72.89% | -23.25% | -55.31% |
| Operating Income | -38.82% | 35.76% | 72.89% | 23.25% | 55.31% |
| Income Before Tax | -13.98% | 19.81% | 71.20% | 5.22% | 62.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.98% | 19.81% | 71.20% | 5.22% | 62.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.88% | 48.13% | 71.20% | 5.22% | 62.28% |
| EBIT | -38.82% | 35.76% | 72.89% | 23.25% | 55.31% |
| EBITDA | -40.77% | 38.63% | 75.28% | 24.95% | 57.51% |
| EPS Basic | 41.08% | 57.18% | 80.72% | 44.98% | 78.69% |
| Normalized Basic EPS | 45.28% | 75.61% | 81.11% | 44.98% | 78.69% |
| EPS Diluted | 41.08% | 57.18% | 80.72% | 44.98% | 78.69% |
| Normalized Diluted EPS | 45.28% | 75.61% | 81.11% | 44.98% | 78.69% |
| Average Basic Shares Outstanding | 72.92% | 21.13% | 49.37% | 72.28% | 76.98% |
| Average Diluted Shares Outstanding | 72.92% | 21.13% | 49.37% | 72.28% | 76.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |